Navigation Links
Valeant Pharmaceuticals Announces Publication of Retigabine Phase 2,Study Data in Neurology

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Apr 10, 2007 - Valeant Pharmaceuticals International (NYSE:VRX) announced today the publication of Phase 2 data for retigabine, a first-in-class neuronal potassium channel opener, in Neurology, a leading independent, scientific journal. The authors concluded that retigabine was efficacious with a demonstrated reduction in monthly seizure rates in this study. Two pivotal Phase 3 trials (RESTORE1 and RESTORE2) are currently underway to further investigate the efficacy and safety of retigabine as an adjunctive treatment for partial-onset seizures in patients with refractory epilepsy.

"There is a clear need for the development of antiepileptic drugs with new mechanisms of action to improve the management of patients whose epilepsy is not controlled by current medications," said Phase 2 study investigator and lead author Roger J. Porter, M.D., University of Pennsylvania. "This new molecule clearly acts by way of a different neuronal mechanism and if approved, would meet a market need. The Phase 2 data published in Neurology indicate that retigabine was efficacious for these hard-to-treat partial seizures in this study."

"We are pleased that these important findings have been published in Neurology," said Wesley P. Wheeler, president, North America and research and development. "Valeant is committed to developing innovative drugs for neurological disorders. We believe that potassium-channel openers with their unique mechanisms of action will advance the treatment of epilepsy."

In the study, investigators found that during the 8-week dose-escalation and 8-week maintenance periods, the addition of retigabine 600, 900 or 1,200 mg per day significantly reduced median monthly seizure frequency compared to baseline by 23, 29 and 35 percent, respectively. The reductions in the 900 and 1,200 mg groups were significantly greater than in the placebo group (13 percent vs. base
'"/>




Page: 1 2 3

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:7/25/2014)... , July 25, 2014  Corporate libraries are ... understanding new advancements in technology and how to cope ... libraries in the pharmaceutical and medical device industries are ... the information and services they provide. ... LLC there are many forces of change that leading ...
(Date:7/25/2014)... /PRNewswire-iReach/ -- "Australia Capsule Endoscopy Systems Market Outlook to ... Endoscopy Systems market. The report provides value, in millions ... (in US dollars) within market segments: Photo ... Endoscopes , Capsule Endoscopy Data Recorders , ... provides company shares and distribution shares data for each ...
(Date:7/25/2014)...  Smile Train and its technology partner BioDigital have ... Simulator among leading global health innovations in The Hive ... Washington, D.C. at The John F. ... "Smile Train is honored to be represented through our ... in health and medicine that TEDMED unites each year," ...
Breaking Medicine Technology:Forces of Change Reshaping Corporate Libraries & Information Services 2Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 2Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 3Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 4Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 5Smile Train and BioDigital Selected to Showcase Virtual Surgery Simulator in The Hive at TEDMED 2014 2Smile Train and BioDigital Selected to Showcase Virtual Surgery Simulator in The Hive at TEDMED 2014 3
(Date:7/28/2014)... The report “Industrial Enzymes Market by Types ... Agents, Bio-Fuel, Animal Feed), & Geography - Global ... the global industrial enzymes market with analysis and ... It also identifies driving and restraining factors for ... trends, opportunities, burning issues, winning imperatives, and challenges. ...
(Date:7/28/2014)... 2014 "Fist bumping" transmits significantly fewer bacteria ... the cultural expectation of hand-to-hand contact between patients ... the August issue of the American Journal ... the Association for Professionals in Infection Control and ... Institute of Biological, Environmental, and Rural Sciences at ...
(Date:7/28/2014)... Qualis Health, one of the ... has published a complimentary, online toolkit that provides ... and families in infection control. Tested and ... toolkit provides a step-by-step roadmap for implementing an ... families early in a hospital stay. , “Across ...
(Date:7/28/2014)... July 28, 2014 Recent research has ... all day for years can lead to a range ... disease. But using a standing desk, or an adjustable ... often driving office workers back to a seated position. ... are designed to alleviate this leg pain and fatigue ...
(Date:7/28/2014)... Thompson HealthDay Reporter ... prematurely appear to have a slightly increased risk of ... adulthood, Swedish researchers report. Doctors have previously suspected ... a raised risk of deep vein thrombosis and pulmonary ... the veins, the researchers noted in background information. ...
Breaking Medicine News(10 mins):Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 2Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 3Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 4Health News:Fist-bumping beats germ-spreading handshake, study reports 2Health News:Patient Engagement in Hospital Infection Control: Online Toolkit Provides a New Solution 2Health News:New Standing Desk Anti-fatigue Mats from Martinson-Nicholls Reduce Leg Fatigue and Discomfort Working at Standing and Sit-to-Stand Desks 2Health News:Preemies May Have Higher Risk of Blood Clots, Even as Adults 2Health News:Preemies May Have Higher Risk of Blood Clots, Even as Adults 3
... in 10 men is affected, and a depressed partner can ... News) -- Although many people know that new moms are ... child, new research suggests that about 10 percent of new ... the researchers found that if the mother experiences postpartum depression, ...
... Tomography (PET) scanning and a new probe developed by ... of the immune system, providing a non-invasive and much ... The probes, the commonly used FDG that measures cellular ... measures the activity of a distinct biochemical pathway, work ...
... release is available in German . ... there are a large class of reports by eyewitnesses having ... of these apparent fire balls for a long time. Now ... magnetic field of long lightning strokes may produce the image ...
... identified an important cancer gene that could lead to more ... a disease which currently has a poor prognosis. The ... was one of a number of significant genetic differences found ... are the most common brain tumour in children. Clinicians ...
... ... at Clinicians’ Fingertips at the Point of Care or Anywhere, , ... Little Falls, NJ (PRWEB) May 18, ... medical education (CME/CE) activities, has achieved new status as an approved iPhone application developer. ...
... to ongoing health risks , TUESDAY, May 18 ... smoke, dust, fumes and gases among those involved in ... Center ultimately compromised the workers, sense of smell, new ... ability to detect odors and irritants, researchers at the ...
Cached Medicine News:Health News:Postpartum Depression Can Strike New Dads 2Health News:Postpartum Depression Can Strike New Dads 3Health News:PET scanning probes reveal different cell function within the immune system 2Health News:Mysterious ball lightning: Illusion or reality? 2Health News:Genetics of children's brain tumor unlocked 2Health News:Projects In Knowledge Launches Free iPhone App of Living Medical Textbook Neurology: Multiple Sclerosis 2010 Edition 2Health News:Projects In Knowledge Launches Free iPhone App of Living Medical Textbook Neurology: Multiple Sclerosis 2010 Edition 3Health News:Lost Sense of Smell Noted Among Ground Zero Workers Post-9/11 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: